Testing effectiveness (Phase 2)WithdrawnNCT02719015
What this trial is testing
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
Who this might be right for
Melanoma
M.D. Anderson Cancer Center